Research directions
Centre de thérapies expérimentales
Activité de recherches: dans les domaines suivants :
- Immunologie antitumorale
- Thérapie cellulaire personnalisée
- Profile fonctionnel de lymphocytes spécifiques
Biblio récente :
1: S. Bobisse, R. Genolet, A. Roberti, J. L. Tanyi, J. Racle, B. J. Stevenson, C. Iseli, A. Michel, MA Le Bitoux, P. Guillaume, J. Schmidt, V. Bianchi, D. Dangaj, C. Fenwick, L. Derré, I. Xenarios, O. Michielin, P. Romero, D. S. Monos, V. Zoete, D. Gfeller, L. E. Kandalaft, G. Coukos, A. Harari. Sensitive and Frequent Identification of High Avidity Neo-epitope Specific CD8+ T-cells in Immunotherapy-naïve Ovarian Cancer. Nature Communications (2018).
2: J. L. Tanyi, S. Bobisse, E. Ophir, S. Tuyaerts, A. Roberti, R. Genolet, P. Baumgartner, B. J. Stevenson, C. Iseli, D. Dangaj, B. Czerniecki, A. Semilietof, J. Racle, A. Michel, I. Xenarios, C. Chiang, D. S. Monos, D. A. Torigian, H. L. Nisenbaum, O. Michielin, C. H. June, B. L. Levine, D. J Powel Jr, D. Gfeller, R. Mick, U. Dafni, V. Zoete, A. Harari, G. Coukos & L. E. Kandalaft. Personalized Cancer Vaccine Effectively Mobilizes Antitumor Immunity in Ovarian Cancer. Science Transl Med (2018).
3: J. Racle, J. Michaux, G.A. Rockinger, M. Arnaud, S. Bobisse, C. Chong, P. Guillaume, G. Coukos, A. Harari, C. Jandus, M. Bassani-Sternberg & D. Gfeller. Deep motif deconvolution of HLA-II peptidomes for robust class II epitope predictions. Nature Biotechnology (2019).
4: M. Broggi, L. Maillat, C. Clement, N. Bordry, P. Corthésy, A. Auger, M. Matter, R. Hamelin, L. Potin, D. Demurtas, E. Romano, A. Harari, D. Speiser, L. Santambrogio & M. Swartz. Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients. Journal of Experimental Medicine (2019).
